An observational study in Prostate Cancer, sponsored by University of California, San Francisco. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by University of California, San Francisco · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Prostatic Neoplasms by University of California, San Francisco — 9 open to participants now, 14 under way, none of them phase 3. Prostatic Neoplasms · University of California, San Francisco.
Among the 57 studies in Prostatic Neoplasms by University of California, San Francisco, this one is one of 3 that started in 2021, is one of 9 observational ones, reaches primary completion later than 1 of the 13 other live ones, and was the 50th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →9 of the 57 studies in Prostatic Neoplasms by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+ · Men only
University of California, San Francisco · Sites in United States
Ages 18+ · Men only
University of California, San Francisco · Sites in United States
Ages 18+ · Men only
University of California, San Francisco · Sites in United States
Ages 18+ · Men only
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 19 · Phase 3 2
First in 1993; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is below the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 42 across the 47 interventional studies, 87 across the 8 observational. Of the 42 that completed or were terminated, 17 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
8 of the studies in Prostatic Neoplasms by University of California, San Francisco that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05435495University of California, San FranciscoMechanisms of Resistance to PSMA Radioligand Therapy | 2026-12-31 |
| NCT04763980University of California, San FranciscoCommunity-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer | 2027-03-31 |
| NCT05056077University of California, San FranciscoImproving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit) | 2027-04-30 |
| NCT02735252University of California, San FranciscoPROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer | 2027-05-31 |
| NCT05766371University of California, San FranciscoPembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | 2027-05-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 57 studies in Prostatic Neoplasms by University of California, San Francisco, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
PRIMARY OBJECTIVES:
I. To determine the relationship between whole body tumor absorbed dose and response Lutetium based prostate-specific membrane antigen-targeted radioligand therapy (177Lu-PSMA-RLT).
II. To determine the relationship between Post-Operative Radiation Therapy Outcomes Score (PORTOS) score and response to 177Lu-PSMA-RLT.
III. To determine the relative importance of radiation dose (whole body tumor absorbed dose) and radiation sensitivity (PORTOS score) as a marker of response to 177Lu-PSMA-RLT.
EXPLORATORY OBJECTIVES:
I. To develop novel signature of radiation sensitivity.
II. To evaluate tumor biopsies to understand mechanisms of resistance.
III. To understand utility of post-cycle 4 single-photon emission computed tomography (SPECT/CT) to evaluate treatment response.
Study participants will undergo a biopsy and blood draw prior to the initiation of planned therapy, as well as SPECT/CT imaging performed after the first and fourth treatments. One SPECT/CT scan will be performed 24 (+/- 6) after the first treatment, and after the fourth treatment, a 24 +/- 6-hour post-treatment SPECT/CT will be performed. Additionally, study participants may choose to undergo optional biopsy and blood draw at time of progression.
Participants will be selected from patients enrolled on Lutetium based PSMA-RLTs and expected to receiving at least four cycles of PSMA-RLT
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergoing PSMA targeted radioligand therapy with at least four cycles of treatment planned will undergo the following: SPECT/CTs will be performed 24 hours after the first treatment and after the fourth treatment, a tumor biopsy will be performed prior to the first 177Lu-PSMA radioligand therapy, a blood will be drawn prior to treatment for future research, and an optional tumor biopsy and blood draw for future research, may also be obtained at time of progression.
Procedure: Single-photon emission computed tomography · Procedure: Blood Draw · Procedure: Tumor Biopsy
Imaging procedure
Also known as: SPECT/CT
Blood draw for future research tests (45-60 mL).
Guided biopsy of lesion
Also known as: Biopsy
Mean whole body tumor absorbed dose (WB Dose) across all metastatic lesions
The unit density sphere model will be implemented using OLINDA, a second-generation personal computer software for internal dose assessment in nuclear medicine to measure mean dose across all metastatic lesions. This approach uses the three time-point SPECT/CTs to create a whole-body dose map, which can then be segmented. Using OLINDA, the total dose to each tumor will be calculated as the integral of activity over time estimated out to 500 hours. Dose will be calculated in gray (Gy).
Time frame: Up to 6 months
Median PORTOS score
PORTOS is a gene signature that predicts salvage radiation success. A PORTOS score of zero (called a "low" PORTOS) means it predicts no benefit from salvage radiotherapy. A PORTOS greater than zero (called a "high" PORTOS score) predicts a benefit from salvage radiation.
Time frame: Up to 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2021 (actual). Primary completion is estimated for Dec 2026, 62 months after the start.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 62 months is close to that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →